Clinical trial
A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple…
NCT00326300 · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Industry · Completed
Key facts
| NCT number | NCT00326300 |
|---|---|
| Title | A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder |
| Official title | An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder |
| Lead sponsor | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | methylphenidate hydrochloride extended-release tablets |
| Enrollment | 560 |
| Start date | Apr 1, 2006 |
| Completion | Aug 1, 2007 |
| First posted | May 16, 2006 |
| Last update posted | May 24, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: